AASLD Guidelines for Treatment of Chronic Hepatitis B
By N. Terrault, N. Bzowej, Kyong‐Mi Chang, Jessica P. Hwang, M. Jonas, M. H. Murad. Hepatology, 2015
1,875 citations recorded by the source corpus.
Guiding Principles This document presents official recommendations of the American Association for the Study of Liver Diseases (AASLD) on the treatment of chronic hepatitis B (CHB) virus (HBV) infection in adults and children. Unlike previous AASLD practice guidelines, this guideline was developed in compliance with the Institute of Medicine standards for trustworthy practice guidelines and uses the Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach. Multiple systematic reviews of the literature were conducted to support the recommendations in this practice guideline. An enhanced understanding of this guideline will be obtained by reading the applicable portions of the systematic reviews. This guideline focuses on using antiviral therapy in chronic HBV infection and does not address other related and important issues, such as screening, prevention, and surveillance. For broader issues related to diagnosis, surveillance, and prevention as well as treatment in special populations (e.g., liver transplant recipients) that are not addressed by this guideline, the previous AASLD guideline and recent World Health Organization (WHO) guideline are excellent additional resources. Objectives Guideline developers from the AASLD formulated a list of discrete questions that physicians are faced with in daily practice. These questions were: 1. Should adults with immune active CHB be treated with antiviral therapy to decrease liverrelated complications? 2. Should adults with immune-tolerant infection be treated with antiviral therapy to decrease liverrelated complications? 3. Should antiviral therapy be discontinued in hepatitis B e antigen (HBeAg)-positive persons who have developed HBeAg seroconversion on therapy? 4. Should antiviral therapy be discontinued in persons with HBeAg-negative infection with sustained HBV DNA suppression on therapy? 5. In HBV-monoinfected persons, does entecavir therapy, when compared to tenofovir therapy, have a different impact on renal and bone health? 6. Is there a benefit to adding a second antiviral agent in persons with persistent low levels of viremia while being treated with either tenofovir or entecavir? 7. Should persons with compensated cirrhosis and low levels of viremia be treated with antiviral agents? 8. Should pregnant women who are hepatitis B surface antigen (HBsAg) positive with high viral load receive antiviral treatment in the third trimester to prevent perinatal transmission of HBV? 9. Should children with HBeAg-positive CHB be treated with antiviral therapy to decrease liverrelated complications?
Subfields: Epidemiology, Hepatology
View Paper: https://www.semanticscholar.org/paper/4c063122a4ef0ed51924aaa86de6d9a69fdd71a4
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Hepatology
Citations in the corpus
- Shared and Distinct Functions of Type I and Type III Interferons (2019, neutral): “…inhibited growth of several different tumor cell lines and diminished local and metastatic tumor formation in mice including cancers from lung, liver, breast, and prostate (Abushahba et al., 2010; Lasfar et al., 2016; Li et al., 2008; Numasaki et al., 2007; Sato et al., 2006; Tezuka et al., 2012).”
- Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. (2017, background): “[4] Terrault NA, Bzowej NH, Chang K, Hwang JP, Jonas MM, Murad MH.”